Perritt Capital Management’s Anika Therapeutics ANIK Stock Holding History

Perritt Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-12,000	Closed	-$556K	–	252
2014 Q2	$556K	Sell	12,000 -145,000	-92%	-$6.45M	0.09%	210
2014 Q1	$6.45M	Sell	157,000 -115,500	-42%	-$4.29M	1.03%	15
2013 Q4	$10.4M	Sell	272,500 -5,000	-2%	-$154K	1.72%	1
2013 Q3	$6.63M	Hold	277,500	–	–	1.29%	9
2013 Q2	$4.72M	Buy	+277,500	New	+$4M	1.06%	20

Other funds holding ANIK

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GAM

Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return

Perritt Capital Management's ANIK Position: Q3 2014 in Review

Perritt Capital Management sold out of Anika Therapeutics (ANIK) in Q3 2014, closing a stake of 12,000 shares — an estimated $556K sold.

Perritt Capital Management first reported a position in ANIK in Q2 2013 and held it in 5 quarters. The position peaked at $10.4M in Q4 2013. 153 funds tracked by Wall St. Rank hold ANIK as of Q3 2014.

Perritt Capital Management reported no remaining Anika Therapeutics position as of Q3 2014 after selling out during the quarter.
Perritt Capital Management sold 12,000 Anika Therapeutics shares in Q3 2014, an estimated $556K.
Perritt Capital Management first reported a position in Anika Therapeutics in Q2 2013 and held it in 5 quarters.
Perritt Capital Management's Anika Therapeutics position peaked at $10.4M in Q4 2013.
153 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2014.

Based on Perritt Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.